Compare Enveric Biosciences Inc (ENVB) vs Five9 Inc (FIVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Five9 Inc — how do they compare? Enveric Biosciences Inc trades at $1.41 (market cap $5.32M), while Five9 Inc trades at $24.94 (market cap $1.90B). The key difference: Five9 Inc is far larger — about 357.1× Enveric Biosciences Inc's market cap, and Five9 Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | FIVN | |
|---|---|---|
Market Cap | $5.32M | $1.90B |
Sector | Health | Technology |
52-Week High | $17.40 | $29.16 |
52-Week Low | $1.28 | $13.61 |
Enterprise Value | $408.82K | $1.98B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
Five9 (FIVN) trades at $25.58, down 0.89% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $27.00. The company has shown consistent revenue growth, reaching $1.15 billion in 2025, and has beaten earnings estimates for the last three quarters. Recent news highlights include new executive appointments and AI product launches, though some legal scrutiny regarding fiduciary duties exists.
The outlook is positive given strong earnings beats and revenue growth, but risks include high valuation multiples, negative net cash flow, and ongoing legal investigations. Analyst sentiment remains largely bullish, supporting potential upside to the price target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →
